Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000823935 | SCV000964810 | likely benign | DNA ligase IV deficiency | 2025-01-21 | criteria provided, single submitter | clinical testing | |
New York Genome Center | RCV000823935 | SCV002099178 | uncertain significance | DNA ligase IV deficiency | 2021-03-27 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000823935 | SCV003814605 | uncertain significance | DNA ligase IV deficiency | 2020-08-04 | criteria provided, single submitter | clinical testing | |
Center for Genomics, |
RCV003224478 | SCV003920149 | uncertain significance | DNA ligase IV deficiency; Multiple myeloma | 2021-03-30 | criteria provided, single submitter | clinical testing | LIG4 NM_002312.3 exon 2 p.Ile238Val (c.712A>G): This variant has not been reported in the literature but is present in 0.04% (10/24894) of African alleles in the Genome Aggregation Database (https://gnomad.broadinstitute.org/variant/13-108862905-T-C). This variant amino acid Valine (Val) is present in >30 species; this suggests that this variant may not impact the protein. Additional computational prediction tools do not suggest an impact. In summary, data on this variant is insufficient for disease classification. Therefore, the clinical significance of this variant is uncertain. |